188 related articles for article (PubMed ID: 35455984)
21. Myelin Basic Protein-Induced Production of Tumor Necrosis Factor-α and Interleukin-6, and Presentation of the Immunodominant Peptide MBP85-99 by B Cells from Patients with Relapsing-Remitting Multiple Sclerosis.
Nielsen CH; Börnsen L; Sellebjerg F; Brimnes MK
PLoS One; 2016; 11(1):e0146971. PubMed ID: 26756931
[TBL] [Abstract][Full Text] [Related]
22. Excessive CD4+ T cells co-expressing interleukin-17 and interferon-γ in patients with Behçet's disease.
Shimizu J; Takai K; Fujiwara N; Arimitsu N; Ueda Y; Wakisaka S; Yoshikawa H; Kaneko F; Suzuki T; Suzuki N
Clin Exp Immunol; 2012 Apr; 168(1):68-74. PubMed ID: 22385240
[TBL] [Abstract][Full Text] [Related]
23. Laboratory and clinical correlates of brain atrophy in Neuro-Behçet's disease.
Gündüz T; Kürtüncü M; Matur Z; Tüzün E; Limon U; Tanyıldız B; İzgi B; Erdoğan N; Öge AE; Gürvit H; Bilgiç B; Akman-Demir G
J Neurol Sci; 2020 Jul; 414():116831. PubMed ID: 32380297
[TBL] [Abstract][Full Text] [Related]
24. Cerebrospinal fluid interleukin-6 in progressive Neuro-Behçet's syndrome.
Hirohata S; Isshi K; Oguchi H; Ohse T; Haraoka H; Takeuchi A; Hashimoto T
Clin Immunol Immunopathol; 1997 Jan; 82(1):12-7. PubMed ID: 9000037
[TBL] [Abstract][Full Text] [Related]
25. Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein.
Harp CT; Ireland S; Davis LS; Remington G; Cassidy B; Cravens PD; Stuve O; Lovett-Racke AE; Eagar TN; Greenberg BM; Racke MK; Cowell LG; Karandikar NJ; Frohman EM; Monson NL
Eur J Immunol; 2010 Oct; 40(10):2942-56. PubMed ID: 20812237
[TBL] [Abstract][Full Text] [Related]
26. VEGF and mRNA VEGF expression in CSF from Behçet's disease with neurological involvement.
Hamzaoui K; Ayed K; Hamza M; Hamzaoui A
J Neuroimmunol; 2009 Aug; 213(1-2):148-53. PubMed ID: 19493574
[TBL] [Abstract][Full Text] [Related]
27. T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients.
Ghezzi L; Cantoni C; Cignarella F; Bollman B; Cross AH; Salter A; Galimberti D; Cella M; Piccio L
Mult Scler; 2020 Sep; 26(10):1172-1186. PubMed ID: 31237799
[TBL] [Abstract][Full Text] [Related]
28. Cognitive impairment in neuro-Behcet's disease and multiple sclerosis: a comparative study.
Gündüz T; Emir Ö; Kürtüncü M; Mutlu M; Tumaç A; Akca S; Coban O; Bahar S; Öktem-Tanör Ö; Tüzün E; Eraksoy M; Gürvit H; Akman-Demir G
Int J Neurosci; 2012 Nov; 122(11):650-6. PubMed ID: 22720779
[TBL] [Abstract][Full Text] [Related]
29. CSF levels of cytokines in neuro-Behçet's disease.
Borhani Haghighi A; Ittehadi H; Nikseresht AR; Rahmati J; Poorjahromi SG; Pourabbas B; Nazarinia MA; Habibagahi Z; Fattahi MJ; Ghaderi A
Clin Neurol Neurosurg; 2009 Jul; 111(6):507-10. PubMed ID: 19303205
[TBL] [Abstract][Full Text] [Related]
30. Sexual dysfunction in Neuro-Behcet's disease.
Hayriye Sorgun M; Kuzu M; Erdoğan S; Yucesan C
J Clin Neurosci; 2020 Aug; 78():211-214. PubMed ID: 32360162
[TBL] [Abstract][Full Text] [Related]
31. Behçet's disease patients with multiple sclerosis-like features: discriminative value of Barkhof criteria.
Akman-Demir G; Mutlu M; Kiyat-Atamer A; Shugaiv E; Kurtuncu M; Tugal-Tutkun I; Tuzun E; Eraksoy M; Bahar S
Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S80-4. PubMed ID: 26486298
[TBL] [Abstract][Full Text] [Related]
32. Anti-alpha B-crystallin immunoreactivity in inflammatory nervous system diseases.
Celet B; Akman-Demir G; Serdaroğlu P; Yentür SP; Taşci B; van Noort JM; Eraksoy M; Saruhan-Direskeneli G
J Neurol; 2000 Dec; 247(12):935-9. PubMed ID: 11200685
[TBL] [Abstract][Full Text] [Related]
33. A Systematic Review of Neurocognitive Functioning in Behçet's Disease.
Fisher CA; Bernard C
Neuropsychol Rev; 2019 Dec; 29(4):498-521. PubMed ID: 31494834
[TBL] [Abstract][Full Text] [Related]
34. SNP-mediated binding of TBX1 to the enhancer element of
Tan H; Su G; Tan X; Qin Y; Chen L; Yuan G; Kijlstra A; Yang P
Epigenomics; 2021 Oct; 13(19):1523-1537. PubMed ID: 34612069
[TBL] [Abstract][Full Text] [Related]
35. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis.
Matsushita T; Tateishi T; Isobe N; Yonekawa T; Yamasaki R; Matsuse D; Murai H; Kira J
PLoS One; 2013; 8(4):e61835. PubMed ID: 23637915
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations.
Kalra S; Silman A; Akman-Demir G; Bohlega S; Borhani-Haghighi A; Constantinescu CS; Houman H; Mahr A; Salvarani C; Sfikakis PP; Siva A; Al-Araji A
J Neurol; 2014 Sep; 261(9):1662-76. PubMed ID: 24366648
[TBL] [Abstract][Full Text] [Related]
37. Neuro-behçet's disease in South Korea: clinical characteristics and treatment response.
Yoon DL; Kim YJ; Koo BS; Kim YG; Lee CK; Yoo B
Int J Rheum Dis; 2014 May; 17(4):453-8. PubMed ID: 24506839
[TBL] [Abstract][Full Text] [Related]
38. Enhanced NLRP3 and DEFA1B Expression During the Active Stage of Parenchymal Neuro-Behçet's Disease.
Ugurel E; Erdag E; Kucukali CI; Olcay A; Sanli E; Akbayir E; Kurtuncu M; Gunduz T; Yilmaz V; Tuzun E; Vural B
In Vivo; 2019; 33(5):1493-1497. PubMed ID: 31471397
[TBL] [Abstract][Full Text] [Related]
39. Olfactory Dysfunction Associated With Neuro-Behçet Disease.
Doğan R; Ertaş B; Özücer B; Birday E; Özturan O; Veyseller B
J Craniofac Surg; 2017 Oct; 28(7):e707-e710. PubMed ID: 28863008
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-6 in neuro-Behçet's disease: association with disease subsets and long-term outcome.
Akman-Demir G; Tüzün E; Içöz S; Yeşilot N; Yentür SP; Kürtüncü M; Mutlu M; Saruhan-Direskeneli G
Cytokine; 2008 Dec; 44(3):373-6. PubMed ID: 19010690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
